RT Journal Article
SR Electronic
T1 COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.210480
DO 10.3899/jrheum.210480
A1 Bonnie L.  Bermas
A1 Milena Gianfrancesco
A1 Helen L.  Tanner
A1 Andrea M.  Seet
A1 Mathia C.  Aguiar
A1 Nasra K.  Al Adhoubi
A1 Samar  Al Emadi
A1 Bernardo M.  Cunha
A1 Rachael Flood
A1 Daria A.  Kusevich
A1 Eoghan M.  McCarthy
A1 Naomi J.  Patel
A1 Eric Ruderman
A1 Sebastian E.  Sattui
A1 Savino Sciascia
A1 Faizah Siddique
A1 Maria O.  Valenzuela-Almada
A1 Leanna M.  Wise
A1 Angus B.  Worthing
A1 JoAnn Zell
A1 Suleman Bhana
A1 Wendy Costello
A1 Ali Duarte-Garcia
A1 Rebecca Grainger
A1 Laure Gossec
A1 Jonathan S.  Hausmann
A1 Kimme Hyrich
A1 Saskia Lawson-Tovey
A1 Jean W.  Liew
A1 Emily Sirotich
A1 Jeffrey A.  Sparks
A1 Paul Sufka
A1 Zachary S.  Wallace
A1 Pedro M.  Machado
A1 Anja Strangfeld
A1 Megan E.B.  Clowse
A1 Jinoos Yazdany
A1 Philip C.  Robinson
YR 2021
UL http://www.jrheum.org/content/early/2021/10/10/jrheum.210480.abstract
AB Objective To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection. Methods Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers. Results We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24–45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti–interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir. Conclusion Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.